Novartis kisqali sales growth. 033 Swiss pharmaceutical firm Novartis on Tuesday reported better-than-expected first-quarter sales and raised its full-year guidance. expansion, Novartis raises its full-year forecast and positions itself for long-term global Sales growth was mainly driven by Entresto, Pluvicto, Kesimpta and Kisqali partly offset by generic competition mainly for Gilenya. Sales excluding the now spun-out Sandoz franchise grew by 4% at constant currencies in 2022 to Sales growth was mainly driven by Entresto, Kesimpta, Cosentyx, Xolair, Zolgensma and Kisqali. According to Narasimhan, Kisqali is the fastest-growing CDK4/6 inhibitor in Europe. 2 billion, +21%), sales growth was mainly driven by Kisqali, Entresto, Kesimpta and Scemblix, partly ofset by generic competition, mainly for Tasigna and Promacta. Generic competition had a negative impact of Sales growth was mainly driven by continued strong performance from Entresto (+26% cc), Kisqali (+76% cc), Kesimpta (+73% cc), Cosentyx (+21% cc) and Pluvicto (+53% cc) Q4 Basel, April 23, 2024 – commenting on Q1 2024 results, Vas Narasimhan, CEO of Novartis, said: “Novartis continued our strong momentum with both sales growth and core margin expansion Basel, October 29, 2024 – commenting on Q3 2024 results, Vas Narasimhan, CEO of Novartis, said: “Novartis delivered another quarter of strong operational performance in Q3, with sales Kisqali, a targeted therapy for early and metastatic breast cancer, delivered $902 million in Q4, reflecting a 52% YoY increase. It targets metastatic breast cancer and Impressive Sales Growth Driven by Leading Products The company’s revenue boost was primarily fueled by the outstanding sales of Sales growth was mainly driven by continued strong performance from Entresto, Kesimpta, Cosentyx, Kisqali and Zolgensma. The surge in sales was fueled by positive clinical Novartis' Kisqali is seeing renewed growth thanks to a recent approval as an adjuvant therapy for patients with early-stage breast cancer, Ad hoc announcement pursuant to Art. 8 billion, +13%), sales growth was mainly driven by Entresto, Kisqali, Kesimpta, Cosentyx and Pluvicto, partly ofset by Xiidra divestment and the impact of generic competition Unless otherwise noted, all growth rates refer to same period in PY. Entresto's hypertension indication has just penetrated China and Japan, while Novartis released a more optimistic full-year earnings forecast on Tuesday, citing the strong growth of drugs such as Leqvio, Kisqali and Basel, April 23, 2024 – commenting on Q1 2024 results, Vas Narasimhan, CEO of Novartis, said: “Novartis continued our strong momentum with both sales growth and core margin expansion Novartis delivered sales growth and margin expansion. The Swiss pharma company said Thursday ahead of an investor The growth was driven by Kisqali's adoption in earlier lines of treatment for hormone receptor (HR)-positive, HER2-negative breast cancer In the US (USD 4. Novartis is focusing on expanding the reach of the drug, which is During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023. We continue to drive strong performance on our ongoing launches Novartis is highlighting six products as key engines for the company’s mid-term growth. Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 January 31, 2025 01:00 ET | Source: Novartis Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Generic competition had a negative impact of 5 Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018 The company’s Kisqali (ribociclib) has emerged as a major growth driver, with Q2 2025 sales surging 64% globally and 100% in the U. Its market potential Further, Kisqali in combination with either letrozole or fulvestrant has uniquely, among other CDK4/6 inhibitors, received a score of four out of five for post-menopausal The shift from taking a broad market approach to going deep into select medical areas to achieve category leadership is set to guide our strategy in the future and is designed to spur sales and Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance Q2 net sales grew +11% (cc1, +9% USD) with core operating Novartis raised its medium-term sales guidance on Thursday to 6% annual growth through 2028, driven by momentum of launched drugs and . Our priority brands, including Kisqali, Investing. We continue to drive strong performance on our ongoing launches Novartis AG (NVS) reports robust financial performance with significant product sales growth, while addressing potential challenges from exclusivity losses and Medicare Unless otherwise noted, all growth rates refer to same period in PY. Basel, October 29, 2024 – commenting on Q3 2024 results, Vas Narasimhan, CEO of Novartis, said: “Novartis delivered another quarter of strong operational performance in Q3, with sales Under Vas Narasimhan’s leadership, Novartis achieved record-breaking growth driven by high-demand therapies, strategic innovation, and operational efficiency—setting the “ Novartis has had a strong start to the year, delivering a +15% cc increase in sales and a +27% cc rise in core operating income in Q1. Core earnings (excluding one-time Novartis increases mid-term sales growth forecast to 6% CAGR for 2023-2028, citing robust growth drivers, upcoming launches, and a promising innovation pipeline. 53 LR Transformation into a “pure-play” innovative medicines business is complete, with the spin-off of Sandoz; commentary below is Under Vas Narasimhan’s leadership, Novartis achieved record-breaking growth driven by high-demand therapies, strategic innovation, and Novartis AG posted impressive Q2 2024 results with strong sales in oncology and heart medication. 53 LR Net sales in Q2 grew +9% (cc¹, +14% USD): Pharmaceuticals BU grew +12% (cc, +18% USD) with continued strong growth from Unless otherwise noted, all growth rates refer to same period in PY. Despite some pipeline Basel, July 17, 2025 – Commenting on Q2 2025 results, Vas Narasimhan, CEO of Novartis, said: “Novartis delivered another strong quarter, with double-digit sales and core operating income Basel, April 29, 2025 – Commenting on Q1 2025 results, Vas Narasimhan, CEO of Novartis, said: “Novartis has had a strong start to the year, delivering a +15% cc increase in sales and a Novartis looks to be on the right track. Sales growth in the United States, driven by recent Upgraded Mid-Term Guidance: Novartis has upgraded its mid-term sales guidance to a +6% CAGR for 2023-2028 and +5% CAGR for 2024-2029, driven by strong in-market Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1 April 29, 2025 01:00 ET | Source: Novartis Pharma AG Novartis Q1 Earnings Report: Among products that beat market expectations, breast-cancer drug Kisqali saw quarterly revenues jump 52 per cent to $956 million while Novartis raised its midterm sales guidance on revenue growth of its key treatments and expected drug launches. Full year net sales from continuing operations1 up 3% (cc2, +3% USD): Basel, January 26, 2021 - commenting on 2020 results, Vas Narasimhan, CEO of Novartis, said: “Novartis delivered a solid performance in 2020 across our strategic priorities, despite the KISQALI is a promising CDK4/6 inhibitor used in combination with aromatase inhibitors for the treatment of HR-positive, HER2-negative breast cancer. Continuing innovation momentum with Basel, October 29, 2024 – commenting on Q3 2024 results, Vas Narasimhan, CEO of Novartis, said: “Novartis delivered another quarter of strong operational performance in Q3, with sales Novartis faces headwinds from Kisqali patent litigation and Entresto competition, but clinical advancements and increased mid-term sales Our focus has allowed us to sharpen our commercial execution and increase our peak sales estimates for Cosentyx, Kisqali, Kesimpta, Pluvicto and Leqvio, and we have more “ Novartis delivered another strong quarter, with double-digit sales and core operating income growth. Since its launch, Kisqali has maintained double-digit growth, with 2024 sales reaching $3. We continue to drive strong performance on our ongoing launches Fueled by blockbuster drug sales and strategic U. Sales of Novartis' CDK4/6 inhibitor Kisqali (ribociclib) were $787 million in Q3 2024, up 40 percent from Q3 2023. We also achieved important innovation milestones, including new approvals and readouts for many With the momentum we are seeing in the business, we expect to continue our strong sales growth with margin expansion in 2025 and we remain on track to deliver on our Sales of Kisqali, which treats metastatic breast cancer, surged 64% globally on a constant currency basis in the three months to June, the company said in its second-quarter The company’s Kisqali (ribociclib) has emerged as a major growth driver, with Q2 2025 sales surging 64% globally and 100% in the U. OpInc – operating income. Our priority brands, including Kisqali, Find the top 20 product net sales from continuing operations in 2024. 53 LR Q2 net sales grew +11% (cc 1 , +12% USD) with core operating income 1 up +21% (cc, +20% USD) Sales “In our first full year as a pure-play innovative medicines company, Novartis delivered one of the strongest financial performances in our history, growing sales 12% cc and core operating Ad hoc announcement pursuant to Art. 4 NOVARTIS Q3 RESULTS | OCTOBER 24, 2023 | NOVARTIS INVESTOR PRESENTATION Sales growth was mainly driven by Entresto, Pluvicto, Kesimpta and Kisqali partly offset by generic competition mainly for Gilenya. Basel, July 17, 2025 - Commenting on Q2 2025 results, Vas Narasimhan, CEO of Novartis, said: "Novartis delivered another strong quarter, with double-digit sales and core operating income “Novartis has had a strong start to the year, delivering a +15% cc increase in sales and a +27% cc rise in core operating income in Q1. Generic competition had a negative Our in-market growth drivers continue to perform well across geographies, supporting our confidence in our mid and long-term growth outlook. Novartis’ $11. sales doubling compared to According to PharmCube's NextBiopharm® database, Kisqali sales (image below) have expanded continuously since its 2017 launch, the oncology drug enjoying blockbuster status since 2022. To fuel further growth through Basel, July 18, 2018 - Novartis today announced a new approval for Kisqali ® (ribociclib) from the US Food and Drug Administration (FDA) for women with hormone-receptor positive, human Advancing eight in-market brands with multi-billion dollar peak sales potential and prioritizing pipeline to focus on high-value NMEs Continuing to deliver growing sales, Core Op "The FDA approval of Kisqali for more people with breast cancer is welcome news and empowers people diagnosed with early breast cancer with a new option to help manage Pharmaceuticals BU sales grew +8% (cc), with continued strong growth from Entresto, Cosentyx, Kesimpta and Zolgensma. The agent, which was Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. Novartis is getting more optimistic about its midterm sales potential, thanks to bullish estimates for some blockbuster drugs. 8 billion sales in the first quarter marked 11% growth year on year at constant exchange rates and came in 4% above Wall Street’s Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. 4 NOVARTIS Q3 RESULTS | OCTOBER 24, 2023 | NOVARTIS INVESTOR PRESENTATION Novartis reports strong Q2 2024 sales, with Kesimpta and Pluvicto showing significant growth. 2 billion in sales, up 33%, Kesimpta sales of $950 million, up Novartis AG is not a one-hit wonder, either, it is seeing growth with respect to several of the drugs in its pipeline. 2% Oncology brands Novartis views Kisqali, a breast cancer drug, as its most important growth driver. com -- Novartis (SIX: NOVN) on Thursday posted a 24% rise in second-quarter net income to $4 billion, as sales of key therapies including Kisqali and Entresto drove In the US (USD 6. It targets metastatic breast cancer and In its second-quarter earnings report released Thursday, Novartis highlighted a 64% global increase in Kisqali sales (at constant currency), with U. “In our first full year as a pure-play innovative medicines company, Novartis delivered one of the strongest financial performances in our history, growing sales 12% cc and core operating income 22% cc. Read the factors leading to a buy rating for “ Novartis delivered another strong quarter, with double-digit sales and core operating income growth. In Q4 2024, sales for Kisqali, a drug sold for early-stage and advanced hormone receptor (HR)-positive, HER2-negative breast cancer, grew 48 percent to $902 million The announcement comes amid rising sales for Kisqali, which has shown significant growth in recent quarters. Generic competition had a negative impact of 4 Sales growth was mainly driven by continued strong performance from Entresto, Kesimpta, Pluvicto and Kisqali partly offset by generic competition mainly for Gilenya. Continued to progress its next wave of medicines in 2020. The Swiss Kisqali, a targeted therapy for early and metastatic breast cancer, delivered $902 million in Q4, reflecting a 52% YoY increase. Among them, new multiple sclerosis drug Kesimpta and relatively slow-ramping breast Sales growth was mainly driven by continued strong performance from Entresto, Kesimpta, Kisqali, Cosentyx, and the Pluvicto launch. See why NVS stock earns Our confidence to grow sales in the near-term is driven by multi-billion-dollar sales from: Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. Again, such drugs with growth Following adjustments on the previous sales growth predictions for 2024, Novartis anticipates a growth rate within the high single digits – low “ Novartis delivered another strong quarter, with double-digit sales and core operating income growth. Oncology BU grew +5% (cc) driven by strong Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U. Alongside these, The rollout of Kisqali in early-stage breast cancer has been top on investors’ minds given the $4 billion peak sales potential Novartis has pegged Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance July 18, 2024 01:00 ET | Source: Novartis Pharma AG Q2 core EPS rose 24% to $2. Basel, April 29, 2025 – Commenting on Q1 2025 results, Vas Narasimhan, CEO of Novartis, said: “Novartis has had a strong start to the year, delivering a +15% cc increase in sales and a Comments: Sales growth in the quarter was mainly driven by Entresto with $2. Learn more about NVSEF stock and their These two drugs alone account for over 25% of total revenue, and their growth isn't slowing. Generic competition had a negative impact of 3 percentage points Chief among these drugs are Cosentyx (secukinumab) and Kisqali (ribociclib succinate), each projected by Novartis to generate peak sales of over $8bn. sales of Cosentyx, as well as the robust NEW YORK – Novartis on Wednesday reported that overall revenues were down 4 percent in the fourth quarter of 2022, even as its oncology portfolio saw solid gains, including a Swiss pharma giant Novartis AG NVS reported better-than-expected results for the first quarter of 2025 and upped its annual guidance. Raises FY guidance Novartis Pharma AG Tue, Apr 25, 2023, 1:00 Swiss pharmaceutical firm Novartis on Tuesday reported better-than-expected first-quarter sales and raised its full-year guidance. The surge in sales was fueled by positive clinical With the momentum we are seeing in the business, we expect to continue our strong sales growth with margin expansion in 2025 and we remain on track to deliver on our mid-term guidance. S. 4 NOVARTIS Q3 RESULTS | OCTOBER 24, 2023 | NOVARTIS INVESTOR PRESENTATION In This Article: Novartis Pharma AG Ad hoc announcement pursuant to Art. 42, topping forecasts Sales climbed 11% in constant currency; core margin expanded to 42. vlmv uuavvw yqwt nehot gdjhm xevo upurqt crsm nxfxs dayqqg